

Human ALK-1/ACVRL1 Protein

Cat. No. ALK-HM101

Description

Source	Recombinant Human ALK-1/ACVRL1 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Asp22-Gln118.
Accession	P37023
Molecular Weight	The protein has a predicted MW of 11.5 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.

Assay Data


Tris-Bis PAGE



Human ALK-1/ACVRL1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human ALK-1/ACVRL1 is greater than 95% as determined by SEC-HPLC.